Fidelity
Home > Boards > US Listed > Biotechs > Compugen (CGEN)

Yep its posted:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DAD2 Member Profile
 
Followed By 59
Posts 4,814
Boards Moderated 0
Alias Born 03/11/09
160x600 placeholder
Compugen Says Not Being Investigated in Insider-Trading Probe "Dow Jones News" - 4/7/2014 10:28:32 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 4/7/2014 9:11:39 AM
Compugen Statement Regarding Insider Trading Allegations "Business Wire" - 4/7/2014 9:03:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 3/5/2014 4:11:28 PM
Compugen Ltd. Closes Public Offering of Ordinary Shares "Business Wire" - 3/5/2014 4:05:00 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 2/28/2014 2:49:27 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 2/28/2014 2:47:11 PM
Compugen Ltd. Prices Public Offering of Ordinary Shares "Business Wire" - 2/28/2014 9:15:00 AM
Compugen Ltd. Announces Proposed Public Offering of Ordinary Shares "Business Wire" - 2/27/2014 4:09:00 PM
Compugen to Present Cancer Immunotherapy Programs at Three International Cancer Conferences in March "Business Wire" - 2/20/2014 7:00:00 AM
Annual and Transition Report (foreign Private Issuer) (20-f) "Edgar (US Regulatory)" - 2/18/2014 5:04:30 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 2/14/2014 8:31:33 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 2/11/2014 4:02:28 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 2/11/2014 7:01:51 AM
Compugen Ltd. Reports Fourth Quarter and Calendar 2013 Results "Business Wire" - 2/11/2014 7:00:00 AM
Compugen Fourth Quarter and Yearend 2013 Conference Call Scheduled for Tuesday, February 11, 2014 at 10:00 AM EST "Business Wire" - 2/4/2014 7:00:00 AM
Compugen to Present Predictive Methodology for Discovery of Novel Immune Checkpoints at the Washington BioLeaders Forum "Business Wire" - 1/22/2014 7:00:00 AM
Compugen Announces Addition of Prof. Drew Pardoll to Its Scientific Advisory Board "Business Wire" - 1/21/2014 7:00:00 AM
Compugen to Significantly Expand Immuno-Oncology Activities During 2014 "Business Wire" - 1/7/2014 9:26:00 AM
Compugen Discloses Discovery of Five Potential Cancer Targets for Antibody Drug Conjugate Therapy "Business Wire" - 12/11/2013 7:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/29/2013 9:26:36 AM
Compugen Ltd. Reports Third Quarter 2013 Financial Results "Business Wire" - 10/29/2013 9:25:00 AM
Compugen Third Quarter 2013 Conference Call Scheduled for Tuesday, October 29, 2013 at 10:00 AM EST "Business Wire" - 10/22/2013 7:00:00 AM
Compugen Presents Experimental Results Supporting Induction of Immune Tolerance by CGEN-15001 Drug Candidate "Business Wire" - 10/16/2013 7:00:00 AM
DAD2   Tuesday, 02/07/12 07:23:17 AM
Re: Fa$tlane post# 111
Post # of 144 
Yep its posted:

Zero revenues in the 4th quarter and the net loss for the 4th quarter was $4.4 million.

Might pull back slightly imo.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist